Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -209.73% is 68% below its 3-year average of -125.03%, around the middle of its 3-year range (-437.38%–-66.37%).
As of the fiscal period ended Tuesday, June 30, 2026. 13.31% below its 12-month average of -185.09%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -209.73%.
RETURN ON EQUITY (ROE)
-209.73%
RETURN ON EQUITY (ROE) AVG TTM
-185.09%
RETURN ON EQUITY (ROE) AVG 3Y
-136.83%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-13.31%
CURRENT VS 3Y AVG
-53.27%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-399.23%
vs the sector median at left
Genelux Corporation
Market Cap
$114.34M
Return on Equity (ROE)
-209.73%
TTM Avg
-185.09%
3Y Avg
-136.83%
5Y Avg
N/A
Market Cap
$114.08M
Return on Equity (ROE)
-22.45%
TTM Avg
-22.96%
3Y Avg
-17.88%
5Y Avg
-19.06%
Market Cap
$113.02M
Return on Equity (ROE)
N/A
TTM Avg
129.36%
3Y Avg
-24207.46%
5Y Avg
-16163.58%
Market Cap
$114.06M
Return on Equity (ROE)
-105.40%
TTM Avg
-90.09%
3Y Avg
-60.23%
5Y Avg
-18.64%
Market Cap
$112.94M
Return on Equity (ROE)
-66.12%
TTM Avg
-291.11%
3Y Avg
1023.70%
5Y Avg
687.99%
Market Cap
$115.02M
Return on Equity (ROE)
-478.26%
TTM Avg
-687.50%
3Y Avg
165.05%
5Y Avg
111.70%
Market Cap
$112.69M
Return on Equity (ROE)
N/A
TTM Avg
326.93%
3Y Avg
83.50%
5Y Avg
24.39%
Market Cap
$116.58M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
Market Cap
$109.91M
Return on Equity (ROE)
-80.97%
TTM Avg
-121.11%
3Y Avg
-93.50%
5Y Avg
-70.15%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genelux Corporation (GNLX) | $114.34M | -209.73% | -185.09% | -136.83% | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | -22.45% | -22.96% | -17.88% | -19.06% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.02M | N/A | 129.36% | -24207.46% | -16163.58% |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | -105.40% | -90.09% | -60.23% | -18.64% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | -66.12% | -291.11% | 1023.70% | 687.99% |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.02M | -478.26% | -687.50% | 165.05% | 111.70% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.69M | N/A | 326.93% | 83.50% | 24.39% |
| Coya Therapeutics, Inc. (COYA)vs › | $116.58M | -0.05% | -43.47% | 9.13% | -18.50% |
| Apyx Medical Corporation (APYX)vs › | $109.91M | -80.97% | -121.11% | -93.50% | -70.15% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $108.18M | -60.82% | -19.88% | -19.08% | -15.27% |
ROE
-209.7%
ROA
-129.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -209.73% |
| 2026-03-31 | -138.64% |
| 2025-12-31 | -278.46% |
| 2025-09-30 | -171.45% |
| 2025-06-30 | -127.17% |
| 2025-03-31 | -98.88% |
| 2024-12-31 | -113.68% |
| 2024-09-30 | -83.59% |
| 2024-06-30 | -70.45% |
| 2024-03-31 | -170.93% |
| 2023-12-31 | -145.31% |
| 2023-09-30 | -104.15% |
| 2023-06-30 | -66.37% |
| 2023-03-31 | -437.38% |
